INS and prostate carcinoma: Epidemiological evidence, coupled with the upregulation of insulin-signalling components and insulin-mediated upregulation of CRPC pathways in prostate cancer cells, has collectively rationalised a multidisciplinary approach to treating advanced prostate cancer that incorporates antiandrogen therapy with simultaneous treatment of metabolic side effects induced by ADT.